(Q60018251)
Statements
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients (English)
Jean-Philippe Collet
Frédérick Allanic
Anne Bellemain-Appaix
Guillaume Cayla
Gilles Montalescot
4 October 2011